Sun, Dec 28, 2014, 9:18 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • myprimitivesistas myprimitivesistas Nov 17, 2013 8:46 AM Flag

    Interesting

     

    I am in contact with several Vertex scientists who made it through the lay-off and now they are being re-assigned to a NON-HCV position (CF). It looks to me like they are giving up on HCV and focusing only on CF.

    It looks like they also over-extended their CC a bit:

    Vertex Pharmaceuticals - The Largest Private Construction Project in the US

    AHA is proud to be a part of the design team for the two Vertex Fan Pier towers being constructed in Boston's Seaport district. Vertex Pharmaceutical's relocation from Cambridge to the Boston Seaport has been one of the most talked about stories in the last year as it is the largest private construction project in the US. The two build-to-suit buildings total 1.1MSF, and construction costs are estimated at $900M.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's logical for Vertex to reassign their personnel to the areas that have the best chance for near term commercial success. The company's reorganization is a necessary response to the market realities that have been evolving rapidly in the treatment hepatitis C. It makes the most sense for Vertex to focus it's resources on developing the CF drugs as a priority given it's need to generate increasing revenue next year to replace Incivek. The CF drugs will dramatically improve the quality and length of life in thousands of young people suffering with this otherwise fatal genetic disease. Vertex will have no competition for years given the safety and effectiveness of their drugs to treat CF, and help fund the R&D for other areas of research in the company to develop other potential treatments in CF cancer and chronic MS in the future. If VX 135, 509 and 787 have commercial potential, they will be realized by licensing arrangements with larger pharma interested in co-developing these drugs, to provide deeper pockets to complete clinical trials for regulatory approval on a timely basis and to market these drugs worldwide.

 
VRTX
118.41+3.26(+2.83%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.